GI Innovation Advances Cancer Immunotherapy Pipeline with ASCO Presentation and Phase 2 Trial Approval
核心洞察
GI Innovation (搜索) received approval from Korea's MFDS (搜索) to conduct a Phase 2 clinical trial evaluating GI-102 in combination with Keytruda for treatment-naive metastatic melanoma (搜索) patients.
The company was selected for an oral presentation of Phase 1 data for GI-101A at ASCO 2026, a distinction reserved for high-priority studies chosen from thousands of global submissions.
The Phase 2 trial will be conducted at world-renowned cancer (搜索) centers including Mayo Clinic, MD Anderson, and Memorial Sloan Kettering to compare combination therapy against Keytruda monotherapy.
Korean biopharmaceutical company GI Innovation (搜索) has achieved significant regulatory and academic milestones for its cancer (搜索) immunotherapy pipeline, securing Phase 2 trial approval for GI-102 and earning recognition for an oral presentation at the prestigious ASCO 2026 conference.
Regulatory Approval for Phase 2 Melanoma Trial
GI Innovation (搜索) received approval from Korea's Ministry of Food and Drug Safety (MFDS (搜索)) to conduct a Phase 2 clinical trial evaluating GI-102 in combination with Keytruda (pembrolizumab) for metastatic melanoma (搜索). This approval follows earlier authorization from the U.S. Food and Drug Administration, enabling the company to accelerate global Phase 2 development.
The randomized controlled trial will compare the GI-102 and Keytruda combination therapy against Keytruda monotherapy in treatment-naive metastatic melanoma (搜索) patients. This design represents the gold standard for clinical evaluation, as randomized assignment provides the most objective method for verifying therapeutic efficacy.
If the combination demonstrates superiority over the current standard of care, GI-102 could establish itself as a new first-line treatment option for metastatic melanoma (搜索) while demonstrating its potential as a combination partner in immuno-oncology strategies.
World-Class Clinical Trial Network
The Phase 2 trial will be conducted at hospitals recognized as the world's best by Newsweek in 2026. Participating institutions include Mayo Clinic (ranked No. 1 globally), Cleveland Clinic (No. 2), MD Anderson Cancer Center (No. 1 among cancer (搜索) hospitals), Memorial Sloan Kettering Cancer Center (No. 2 among cancer hospitals), Samsung Medical Center (No. 3 among cancer hospitals), and Asan Medical Center (No. 5 among cancer hospitals).
This collaboration with top-tier global cancer (搜索) centers is expected to generate high-quality data reflecting the clinical expertise of world-renowned researchers, potentially strengthening the regulatory submission package.
ASCO Recognition and Innovation Support
GI Innovation (搜索) was selected for an oral presentation of Phase 1 data for its immuno-oncology drug GI-101A at the American Society of Clinical Oncology (ASCO) 2026 annual meeting, scheduled for May 29 to June 3 in Chicago. This distinction is reserved for only a small number of high-priority studies chosen from thousands of abstracts submitted worldwide.
"The acceptance of GI-101A for an oral presentation at ASCO is a result of having its clinical potential and academic value recognized by a prestigious academic society," said GI Innovation (搜索) CEO Jang Myung-ho. "We will clearly demonstrate the clinical significance of GI-101A and its strategic value as a combination therapy at the presentation."
Regulatory Fast-Track Designation
GI-102 has been selected for "Gilzabi," the MFDS (搜索)'s support program for commercialization of innovative products. This newly introduced program supports rapid commercialization of drug candidates that are innovative, socially urgent, and highly viable for commercialization.
Selected products receive dedicated project manager support and close consultation throughout the entire development cycle. The program links with the fast-track review (GIFT) program and provides systematic support for rapid commercialization, including pre-review of data preparation standards when necessary.
Addressing Unmet Medical Need
CEO Chang Myung-ho highlighted the treatment challenges in Korea's metastatic melanoma (搜索) landscape, noting that "patients find it difficult to receive sufficient treatment benefits due to various constraints, including reimbursement issues." The company aims to provide new treatment options for patients with rare and intractable cancers through early commercialization efforts.
Clinical trials of GI-102 are progressing across multiple development tracks, including subcutaneous monotherapy, combination with antibody-drug conjugates, and combination with Keytruda, positioning the company for potential multiple indication approvals.